ArticleCureus2025
A Pilot Trial of Two-Fraction Stereotactic Body Radiation Therapy for Localized Prostate Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUltra-hypofractionated radiation is a widely adopted treatment for low- and intermediate-risk prostate cancer and is typically given for a duration of five treatments in the United States. There is interest in developing a shorter two-treatment course. We conducted a pilot study of two-fraction ultra-hypofractionated radiation therapy for low- to intermediate-risk prostate cancer to determine safety and preliminary efficacy.
methodsA total of 12 patients were prospectively enrolled in a single-arm pilot study of two-fraction ultra-hypofractionated radiation therapy. Patients were treated with 12.5 Gy in two fractions separated by 2-3 days. All patients had placement of a rectal spacer. Biochemical response was evaluated with prostate-specific antigen (PSA) monitoring, with recurrence defined using the American Society for Therapeutic Radiology and Oncology (ASTRO) Phoenix criteria. Toxicity was graded using the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
resultsMedian follow-up was 4.8 years. This cohort consisted of National Comprehensive Cancer Network (NCCN) intermediate-risk patients (seven NCCN favorable intermediate and five NCCN unfavorable intermediate). The median prostate volume was 30 cc. The median PSA nadir was 0.14 (range <0.01 to 0.82). No patient experienced a biochemical recurrence. No patient experienced grade 2 or worse gastrointestinal (GI) acute or late toxicity. Three of the 12 patients experienced acute grade 2 genitourinary (GU) toxicity, and two of the 12 patients experienced late grade 2 toxicity. No patient experienced grade 3 toxicity.
conclusionsTwo-fraction ultra-hypofractionated radiation to 25 Gy is tolerable with a low rate of long-term toxicity and promising biochemical control. Further research is indicated to evaluate two-fraction regimens for prostate radiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.